Otsu/Shiga, Japan – November 11, 2014 -  Takara Bio Inc. announced that on November 10, 2014, it signed an asset acquisition agreement with StemCells, Inc. (SCI. Head office: CA, the United states) concerning stem cell-related research products marketed by SCI. Under the agreement, Takara Bio will acquire all assets necessary to manufacture and sell these products.

 

SCI develops stem cell therapies primarily involving the central nervous system and manufactures and markets research products using stem cell technology.

 

Under this agreement, Takara Bio acquires all assets necessary to manufacture and sell a group of stem cell related research products mainly comprising stem cell culture media and media for nerve cell differentiation. Takara Bio group will starts manufacturing and marketing of these products from January 2015.

 

This acquisition has only slight effect on estimated consolidated and non-consolidated operating results of the fiscal year ended March 2015.

【Profile of StemCells Inc.】

Company name StemCells, Inc.
Established 1988
Issued capital 551,383 dollars
Representative Martin McGlynn, President and CEO
Head Office 7707 Gateway Blvd., Suite 140 Newark, CA 94560 USA
Major business Development of stem cell therapies primarily involving the central nervous system and manufacturing and marketing research products using stem cell technology. SCI is listed on NASDAQ.
Consolidated sales 1,203,000 dollars (January to December, 2013)
Consolidated number of employees 58 employees (as of December 31, 2013)